Insmed To Present at the H.C. Wainwright Annual Global Life Sciences Conference

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on rare diseases, will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference. The event is scheduled for on-demand viewing on May 24, 2022, at 7:00 a.m. ET, accessible through the company's investor relations site. Insmed is known for its first-in-disease therapy for chronic lung disease and has a pipeline aimed at unmet medical needs in inflammatory and pulmonary disorders. The webcast will be available for 30 days post-presentation.

BRIDGEWATER, NJ,, May 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference.

The fireside chat will become available for on-demand viewing on May 24, 2022 at 7:00 a.m. ET and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the presentation date.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-hc-wainwright-annual-global-life-sciences-conference-301548445.html

SOURCE Insmed Incorporated

FAQ

When will Insmed present at the H.C. Wainwright Annual Global Life Sciences Conference?

Insmed will present at the conference on May 24, 2022, with the fireside chat available for on-demand viewing at 7:00 a.m. ET.

How can I access the Insmed presentation from the H.C. Wainwright Conference?

The presentation can be accessed through the investor relations section of Insmed's website starting May 24, 2022.

What is the focus of Insmed's therapies?

Insmed focuses on transforming the lives of patients with serious and rare diseases, including chronic lung conditions.

How long will the Insmed webcast be available after the conference?

The webcast will be archived and available for viewing for 30 days following the presentation date.

What is Insmed's first commercial product?

Insmed's first commercial product is a first-in-disease therapy approved for treating a chronic, debilitating lung disease.